Dongwha to sell $500 Mil. worth of technologies to P&G.

Dongwha announced at the Press Center on July 2 that the company agreed to sell the technology of DW1350, an innovative new drug for the treatment of osteoporosis, at about U$511 million to P&G, a gigantic American company. The transfer will be the biggest in its kind in the history of Korean pharmaceutical export.

The agreement indicated that the two companies share even all risks in the pr...